Free Trial

BioAtla (BCAB) News Today

BioAtla logo
$2.07
+0.07 (+3.50%)
(As of 05:12 PM ET)
BioAtla, Inc. stock logo
BioAtla (BCAB) to Release Quarterly Earnings on Thursday
BioAtla (NASDAQ:BCAB) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.
BioAtla, Inc. stock logo
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Increase in Short Interest
BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 5,240,000 shares, a growth of 17.2% from the September 30th total of 4,470,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 4.4 days.
BioAtla, Inc. stock logo
636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLC
AQR Capital Management LLC acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 636,136 shares of the company's stock, valued at approximatel
BioAtla, Inc. stock logo
Renaissance Technologies LLC Decreases Stock Holdings in BioAtla, Inc. (NASDAQ:BCAB)
Renaissance Technologies LLC trimmed its holdings in shares of BioAtla, Inc. (NASDAQ:BCAB - Free Report) by 37.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 625,500 shares of the company's stock after selling 370,800 sh
BioAtla: Numerous Catalysts Coming In Q4
BioAtla, Inc. stock logo
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB)
Scion Asset Management LLC purchased a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 633,959 shares of the company's stock, valued at approximately $869,00
BioAtla, Inc. stock logo
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short Interest
BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 4,450,000 shares, a decline of 6.3% from the August 15th total of 4,750,000 shares. Based on an average daily trading volume, of 894,700 shares, the short-interest ratio is presently 5.0 days.
BioAtla, Inc. stock logo
BioAtla (NASDAQ:BCAB) Receives Market Outperform Rating from JMP Securities
JMP Securities reissued a "market outperform" rating and set a $5.00 target price on shares of BioAtla in a research note on Monday.
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky
BioAtla, Inc. stock logo
Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Rises By 18.8%
BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,750,000 shares, a growth of 18.8% from the July 31st total of 4,000,000 shares. Based on an average daily volume of 955,100 shares, the days-to-cover ratio is currently 5.0 days.
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript
BioAtla, Inc. stock logo
BioAtla (NASDAQ:BCAB) Issues Earnings Results, Beats Expectations By $0.01 EPS
BioAtla (NASDAQ:BCAB - Get Free Report) released its earnings results on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. During the same quarter last year, the company posted ($0.75) EPS.
BioAtla, Inc. stock logo
BioAtla (BCAB) Set to Announce Quarterly Earnings on Thursday
BioAtla (NASDAQ:BCAB) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.
BioAtla (BCAB) Receives a Buy from J.P. Morgan
BioAtla, Inc. stock logo
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 24.2% in July
BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 3,980,000 shares, a drop of 24.2% from the June 30th total of 5,250,000 shares. Based on an average daily volume of 880,600 shares, the short-interest ratio is currently 4.5 days.
BioAtla, Inc. stock logo
BioAtla (NASDAQ:BCAB) Trading Down 3.8%
BioAtla (NASDAQ:BCAB) Trading Down 3.8%
BioAtla, Inc. stock logo
BioAtla (NASDAQ:BCAB) Price Target Lowered to $5.00 at JMP Securities
JMP Securities cut their target price on shares of BioAtla from $12.00 to $5.00 and set a "market outperform" rating on the stock in a research report on Thursday.
BioAtla, Inc. stock logo
HC Wainwright Analysts Increase Earnings Estimates for BioAtla, Inc. (NASDAQ:BCAB)
BioAtla, Inc. (NASDAQ:BCAB - Free Report) - HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for BioAtla in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.51) per share for the quarter,
BioAtla, Inc. stock logo
BioAtla (NASDAQ:BCAB) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of BioAtla in a research report on Wednesday.
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.

The Final Frontier (Ad)

And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.

Here’s the full story for you.

BCAB Media Mentions By Week

BCAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCAB
News Sentiment

0.00

0.44

Average
Medical
News Sentiment

BCAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCAB Articles
This Week

2

1

BCAB Articles
Average Week

Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BCAB) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners